Search

Author/Creator Neukirchen, Dorothee

1. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Issue 12 (December 2022)

Authors:
Vlaar, Alexander P J; Witzenrath, Martin; van Paassen, Pieter; Heunks, Leo M A; Mourvillier, Bruno; de Bruin, Sanne; Lim, Endry H T; Brouwer, Matthijs C; Tuinman, Pieter R; Saraiva, José F K; Marx, Gernot; Lobo, Suzana M; Boldo, Rodrigo; Simon-Campos, Jesus A; Cornet, Alexander D; Grebenyuk, Anas...
Journal:
Lancet
Issue:
Volume 10:Issue 12(2022)
Page Start:
1137
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. LB1529. Randomized, Controlled Phase 3 Study of anti-C5a Vilobelimab's Effect on Mortality in Critically Ill COVID-19 Patients: A Therapy for Viral Pneumonia. (15th December 2022)

Authors:
Mourvillier, Bruno; Vlaar, Alexander; Witzenrath, Martin; Bauer, Michael; Heunks, Leo; Vasquez, Luis Hercilla; Welte, Tobias; van Paassen, Pieter; De Bruin, Sanne; Lim, Endry H T; Tuinman, Pieter R; Saraiva, Jose F; Marx, Gernot; Lobo, Suzana Margareth; Boldo, Rodrigo; Simón Campos, Jesus Abraham...
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search